Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 6:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Healthy, Schizophrenia
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 55 Years
Enrollment
1,386 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Infertility, Female, Reproductive Techniques, Assisted, Fertilization in Vitro
Interventions
Intracytoplasmic Sperm Injection (ICSI), Conventional Insemination (IVF)
Procedure
Lead sponsor
Shady Grove Fertility Reproductive Science Center
Other
Eligibility
Female only
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Rockville, Maryland
Completed No phase listed Observational Accepts healthy volunteers

Oocyte Cryopreservation Comparing Fresh and Vitrified Sibling Oocytes

NCT00986687
Conditions
Infertility
Interventions
Not listed
Lead sponsor
UConn Health
Other
Eligibility
21 Years to 37 Years · Female only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Farmington, Connecticut
Completed Not applicable Interventional Accepts healthy volunteers

A Behavioral Intervention With Foster Families

NCT05405972
Conditions
Family Relationship, Sibling Relations, Behavior, Social
Interventions
The Connected Family Series - For Foster Families
Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
7 Years to 85 Years
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Tucson, Arizona
Conditions
Sickle Cell Disease
Interventions
Alemtuzumab, low dose total body irradiation, Sirolimus
Drug
Lead sponsor
Robert Nickel
Other
Eligibility
2 Years to 25 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Chicago, Illinois • New York, New York + 2 more
Conditions
Sickle Cell Disease, Thalassemia, Anemia, Granuloma, Wiskott-Aldrich Syndrome, Chediak Higashi Syndrome, Osteopetrosis, Neutropenia, Thrombocytopenia, Hurler Disease, Niemann-Pick Disease, Fucosidosis
Interventions
Hematopoietic stem cell transplantation
Procedure
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
Up to 21 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Recruiting No phase listed Observational Accepts healthy volunteers

Social Isolation and Aging in Schizophrenia

NCT07419321
Conditions
Schizophrenia and Related Disorders
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
40 Years to 70 Years
Enrollment
650 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Hartford, Connecticut
Terminated Phase 1Phase 2 Interventional Results available

SCID Bu/Flu/ATG Study With T Cell Depletion

NCT02127892
Conditions
Severe Combined Immunodeficiency
Interventions
unrelated BM with T cell depletion, unrelated cord blood, haplo BM with T cell depletion, unrelated PBSC with T cell depletion
Biological · Device
Lead sponsor
Neena Kapoor, M.D.
Other
Eligibility
Up to 21 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Completed Not applicable Interventional Accepts healthy volunteers Results available

HLA-Identical Sibling Renal Transplant Tolerance

NCT00619528
Conditions
Immunosuppression, Kidney Transplantation, Graft Rejection
Interventions
Infusion of Donor Hematopoietic Stem Cells and Campath-1H
Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Fanconi Anemia
Interventions
Anti-Thymocyte Globulin, Cyclophosphamide, Fludarabine, Hematopoietic Stem Cell Transplantation, Methylprednisolone, Filgrastim, Cyclosporine, Mycophenolate Mofetil
Biological · Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 59 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Completed Not applicable Interventional Accepts healthy volunteers

Gluten and Amylase Trypsin Inhibitors (ATI) Free Diet

NCT03443180
Conditions
Type1diabetes
Interventions
Gluten and Amylase Trypsin Inhibitors (ATI)-free diet
Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
2 Years to 23 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Conditions
Hematologic Diseases, Anemia, Sickle Cell, Beta-Thalassemia, Hematopoietic Stem Cell Transplantation
Interventions
Sangstat, Cyclophosphamide, Busulfan, Mycophenolate Mofetil, Cyclosporine, Cord Blood Transplantation
Drug · Procedure
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
3 Years to 14 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
14
States / cities
Oakland, California • Washington D.C., District of Columbia • Jacksonville, Florida + 10 more
Conditions
Acute Myeloid Leukemia in Remission, Adult Acute Lymphoblastic Leukemia in Remission, Chronic Myelogenous Leukemia (CML), Non-Hodgkin's Lymphoma (NHL) or Hodgkin's Disease (HD) in 2nd or Greater Complete Remission, Partial Remission, Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Myelodysplastic Syndrome (MDS), Myeloproliferative Disorders
Interventions
POL6326, Leukapheresis, PBSC Transplant
Drug · Procedure
Lead sponsor
Polyphor Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Kansas City, Kansas • St Louis, Missouri
Conditions
Autism Sibling
Interventions
tele-ImPACT
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
6 Months to 24 Months
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
2
States / cities
Nashville, Tennessee • Austin, Texas
Conditions
Rheumatoid Arthritis, Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
2 Years and older
Enrollment
1,056 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
3
States / cities
Bethesda, Maryland • Research Triangle Park, North Carolina • Madison, Wisconsin
Completed No phase listed Observational

Feasibility Study for PANDAS

NCT00754897
Conditions
Inguinal Hernia, Developmental Delay Disorders
Interventions
Not listed
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 3 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Sickle Cell Disease
Interventions
Alemtuzumab, Fludarabine, Melphalan
Drug
Lead sponsor
Emory University
Other
Eligibility
2 Years to 13 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
13
States / cities
Birmingham, Alabama • Phoenix, Arizona • New Haven, Connecticut + 10 more
Conditions
Defibrillators, Implantable, Myocardial Infarction, Tachycardias, Ventricular
Interventions
ICD
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
2,047 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Completed No phase listed Observational Accepts healthy volunteers

Endothelial Function, Arterial Stiffness and Components

NCT01439217
Conditions
Acute Lymphoblastic Leukemia
Interventions
Not listed
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
8 Years to 28 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
2
States / cities
Baltimore, Maryland
Conditions
Younger Sibling of Child With Autism Spectrum Disorder, Signs of Developmental Delay, Signs of Communication Delay, Signs of Social Delay
Interventions
Infant Achievements, Caregiver Education (CE)
Behavioral
Lead sponsor
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Other
Eligibility
8 Months to 12 Months
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Very Low Birthweight
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
Up to 4 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
2
States / cities
Durham, North Carolina • Raleigh, North Carolina
Conditions
Hematologic Neoplasms
Interventions
AMD3100, Leukopheresis, Stem cell transplant
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
For Donors, Related Donors Giving Peripheral Blood Stem Cells (PBSC) to a Sibling, For Recipients, Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndrome (MDS), Chronic Myelogenous Leukemia (CML), Non-Hodgkins Lymphoma (NHL), Hodgkins Disease (HD), Chronic Lymphocytic Leukemia (CLL)
Interventions
CDX-301, CDX-301 and plerixafor
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
8
States / cities
Los Angeles, California • Atlanta, Georgia • Indianapolis, Indiana + 5 more
Conditions
Kidney Cancer
Interventions
anti-thymocyte globulin, graft-versus-tumor induction therapy, therapeutic allogeneic lymphocytes, cyclophosphamide, fludarabine phosphate, mycophenolate mofetil, tacrolimus, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Rochester, New York